Literatur
-
1
Dent J, Brun J, Fendrick A M. et al. On behalf of the Genval Workshop Group. .
An evidence-based appraisal of reflux disease management - the Genval Workshop Report.
Gut.
1999;
44 (Suppl 2)
1-16
-
2
Inadomi J M, Jamal R, Murata G H. et al .
Step-down management of gastroesophageal reflux disease.
Gastroenterology.
2001;
121 (5)
1095-1100
-
3
Edwards S J, Lind T, Lundell L.
Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis.
Aliment Phamacol Ther.
2001;
15
1729-1736
-
4
Thjodleifsson B, Rindi G, Fiocca R. et al .
A randomized double blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years.
Aliment Pharmacol Ther.
2003;
17
343-351
-
5
Van der Peet D L, Klinkenberg-Knol E C, Eijsbouts Q AJ. et al .
Laparoscopic Nissen fundoplication for the treatment of gastroesophageal reflux disease (GERD); surgery after extensive conservative treatment.
Surg Endosc.
1998;
1
1159-1161
-
6
Campos G M, Peters J H, DeMeester T R. et al .
Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication.
J Gastrointest Surg.
1999;
3 (3)
292-300
-
7
Kahrilas P J.
Management of GERD: Medical versus surgical.
Seminars in Gastrointestinal Disease.
2001a;
12
3-15
-
8
Kahrilas P J.
Surgical therapy for reflux disease.
JAMA.
2001b;
2376-2378
-
9
Galmiche J P, Zerbib F.
Antagonist. Laparoscopic fundoplication is the treatment of choice for gastro-oesophageal reflux disease.
Gut.
2002;
51
472-474
-
10
Lundell L.
Protagonist. Laparoscopic fundoplication is the treatment of choice for gastro-oesophageal reflux disease.
Gut.
2002;
51
468-471
-
11
Parilla P, de Martinez Haro LF, Ortiz A. et al .
Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett’s esophagus.
Ann Surg.
2003;
237
291-298
-
12
Peghini P G, Katz P O, Castell D O.
Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects.
Gastroenterology.
1998;
115 (6)
1335-1339
-
13
Farrell T M, Richardson W S, Trus T L. et al .
Response of atypical symptoms of gastro-oesophageal reflux to antireflux surgery.
Br J Surg.
2001;
88 (12)
1649-1652
-
14
Amin M R, Postma G N, Johnson P. et al .
Proton pump inhibitor resistance in the treatment of laryngopharygeal reflux.
Otolaryngol Head Neck Surg.
2001;
125
374-378
-
15
Reilly J P.
Safety profile of the proton-pump inhibitors.
Am J Health Syst Pharm.
1999;
56 (23, Suppl 4)
S11-17
-
16
Gerson L B, Hatton B N, Ryono R. et al .
Clinical and fiscal impact of lansoprazole intolerance in veterans with gastro-oesophageal reflux disease.
Aliment Pharmacol Ther.
2000;
4 (4)
397-406
-
17
Cordes A, Vogt W, Maier K P.
Pantozol-induzierte Hepatitis.
Dtsch Med Wochenschr.
2003;
128
611-614
-
18
Hungin A P, Rubin G, O'Flanagan H.
Factors influencing compliance in long-term proton pump inhibitor therapy in general practice.
Br J Gen Pract.
1999;
49 (443)
463-464
-
19
Dent J.
Controversies in long-term management of reflux disease.
Baillère’s Clinical Gastroenterology.
2000;
14
811-826
-
20
Romagnuolo J, Meier M A, Sadowski D C.
Medical or surgical therapy for erosive reflux esophagitis: cost utility analysis using a Markov model.
Ann Surg.
2002;
236 (2)
191-202
-
21
O’Boyle C J, Watson D I, DeBeaux A C. et al .
Preoperative prediction of long-term outcome following laparoscopic fundoplication.
ANZ J Surg.
2002;
2
471-475
-
22
Granderath F A, Kamolz T, Schweiger U M. et al .
Outcome after laparoscopic antireflux surgery: fundoplication and re-fundoplication in the elderly.
Chirurg.
2001;
72 (9)
1026-1031
-
23
Klinkenberg-Knol E C, Festen H P, Jansen J B. et al .
Long term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety.
Ann Intern Med.
1994;
121 (3)
161-167
-
24
Klinkenberg-Knol E C, Nelis F, Dent J. et al .
Long term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa.
Gastroenterology.
2000;
118 (4)
661-669
-
25
Peters F T, Ganesh S, Kuipers E J. et al .
Endoscopic regression of Barrett’s oesophagus during omeprazole treatment; a randomised double blind study.
Gut.
1999;
45
489-494
-
26
Vela M F, Camacho Lobato L, Srinivasan R. et al .
Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole.
Gastroenterology.
2001;
120 (7)
1599-1606
-
27
Lundell L, Miettinen P, Myrvold H E. et al .
Continued (5 year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease.
J Am Coll Surg.
2001;
192
172-181
-
28
Taha A S, Angerson W J, Morran C G.
Reflux and Barrett’s oesophagitis after gastric surgery - long-term follow-up and implications for the roles of gastric acid and bile in oesophagitis.
Aliment Pharmacol Ther.
2003;
17
547-552
-
29
Ortiz A, de Martinez H aro LF, Parrilla P. et al .
Conservative treatment versus antireflux surgery in Barrett’s oesophagus: long term results of a prospective study.
Br J Surg.
1996;
83 (2)
274-278
-
30
Spechler S J, Lee E, Ahnen D. et al .
Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial.
JAMA.
2001;
285
2331-2338
-
31
Ye W, Chow W H, Lagergren J. et al .
Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery.
Gastroenterology.
2001;
121 (6)
1286-1293
-
32
Klaus A, Hinder R A.
Medical therapy versus antireflux surgery in Barrett’s esophagus: what is the best therapeutic approach?.
Dig Dis.
2000-2001;
18
224-231
-
33
Gutschow C A, Schröder W, Prenzel K. et al .
Impact of antireflux surgery on Barrett’s esophagus.
Langenbecks Arch Surg.
2002;
387
3 - 4; 138 - 145
-
34
P van, Numans M E, Bonis P A. et al .
Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
Cochrane Database Syst Rev.
2001;
4
CD002095
-
35
Basu K K, Bale R, West K P. et al .
Persistent acid reflux and symptoms in patients with Barrett’s oesophagus on proton-pump inhibitor therapy.
Eur J Gastroenterol Hepatol.
2002;
14 (11)
1187-1192
-
36
You J H, Lee A C, Wong S C. et al .
Low-dose or standard-dose proton pump inhibitors for maintenance therapy of gastro-oesophageal reflux disease: a cost-effectiveness analysis.
Aliment Pharmacol Ther.
2003;
17
785-792
-
37
Leeder P C, Watson D I, Jamieson G G.
Laparoscopic fundoplication for patients with symptoms but no objective evidence of gastroesophageal reflux.
Dis Esoph.
2002;
15 (4)
309-314
-
38
Maziak D E, Todd T RJ, Pearson F G.
Massive hiatus hernia: evaluation and surgical management.
J Thorac Cardiovasc Surg.
1998;
115
53-62
-
39
van Herwaarden M A, Samsom M, Smout A J.
Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxations.
Gastroenterology.
2000;
119 (6)
1439-1446
-
40
Jones M P, Sloan S S, Rabine J C. et al .
Hiatal hernia size is the dominant determinant of esophagitis presence and severity of gastroesophageal reflux disease.
Am J Gastroenterol.
2001;
96
1711-1717
-
41
Avidan B, Sonnenberg A, Schnell T G. et al .
Hiatal hernia size, Barrett’s length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma.
Am J Gastroenterol.
2002;
97 (8)
1930-1936
-
42
Stylopoulos N, Gazelle G S, Rattner D W.
Paraesophageal hernias: operation or observation.
Ann Surg.
2002;
236
492-501
-
43
Kleinmann E, Halbfass H J.
Zur Problematik des „short esophagus” in der laparoskopischen Antirefluxchirurgie.
Chirurg.
2001;
72
408-413
-
44
Streets C G, DeMeester S R, DeMeester T R. et al .
Excellent quality of life after Nissen fundoplication depends on successful elimination of reflux symptoms and not the invasiveness of the surgical approach.
Ann Thorac Surg.
2002;
74 (4)
1019-1024; discussion 1024-1025
-
45
Deschamps C, Allen M S, Trastek V F. et al .
Early experience and learning curve associated with laparoscopic Nissen fundoplication.
J Thorac Cardiovasc Surg.
1998;
115
281-284
-
46
Rantanen T K, Halme T V, Luostarinen M E. et al .
The long term results of open antireflux surgery in a community-based health care center.
Am J Gastroenterol.
1999;
94
1777-1781
-
47
Rydberg L, Ruth M, Abrahamsson H. et al .
Tailoring antireflux surgery: A randomized clinical trial.
World J Surg.
1999;
23
612-618
-
48
Csendes A, Burdiles P, Korn O. et al .
Late results of a randomized clinical trial comparing total fundoplication versus calibration of the cardia with posterior gastropexy.
Br J Surg.
2000;
87 (3)
289-297
-
49
Bais J E, Bartelsman J F, Bonjer H J. et al .
Laparoscopic or conventional Nissen fundoplication for gastro-oesophageal reflux disease: randomised clinical trial. The Netherlands Antireflux Surgery Study Group.
Lancet.
2000;
355
170-174
-
50
Hagedorn C, Lonroth H, Rydberg L. et al .
Long-term efficacy of total (Nissen-Rossetti) and posterior partial (Toupet) fundoplication. Results of a randomized clinical trial.
J Gastrointest Surg.
2002;
31 (6) (4)
540-545
-
51
Hüttl T P, Hohle M, Meyer G. et al .
Antireflux surgery in Germany. Results of a representative survey with analysis of 2,540 antireflux operations.
Chirurg.
2002;
73 (5)
451-461
-
52
Vakil N, Shaw M, Kirby R.
Clinical effectiveness of laparoscopic fundoplication in a U.S. community.
Am J Med.
2003;
1114
1-5
-
53
Tan L C, Samanta S, Hosking S W.
Safe transition from open to laparascopic fundoplication by an established consultant - the importance of repeated audit.
Ann R Coll Surg Engl.
2002;
84
84-88
-
54
Menon V S, Manson J M, Baxter J N.
Laparascopic fundoplication: learning curve and patient satisfaction.
Ann R Coll Surg Engl.
2003;
85
10-13
-
55
Fibbe C, Layer P, Keller J. et al .
Esophageal motility in reflux disease before and after fundoplication: A prospective, randomized, clinical, and manometric study.
Gastroenterology.
2001;
121 (1)
5-14
-
56
Avidan B, Sonnenberg A, Schnell T G. et al .
There are no reliable symptoms for erosive oesophagitis and Barrett’s oesophagus: endoscopic diagnosis is still essential.
Aliment Pharmacol Ther.
2002;
16
735-742
-
57
Khajanchee Y S, O’Rourke R W, Lockhart B. et al .
Postoperative symptoms and failure after antireflux surgery.
Arch Surg.
2002;
137
1008-1013
-
58
Blom D, Peters J H, DeMeester T R. et al .
Physiologic mechanism and preoperative prediction of new-onset dysphagia after laparoscopic Nissen fundoplication.
J Gastrointest Surg.
2002;
6: (1)
22-27; discussion 27-28
-
59
Booth M, Stratford J, Dehn T C.
Preoperative esophageal body motility does not influence the outcome of laparoscopic Nissen fundoplication for gastroesophageal reflux disease.
Dis Esophagus.
2002;
15 (1)
57-60
-
60
Martinez S D, Malagon I B, Garewal H S. et al .
Non-erosive reflux disease (NERD) - acid reflux and symptom patterns.
Aliment Phamacol Ther.
2003;
17
537-545
-
61
Van der Burgh A, Dees J, Hop W C. et al .
Oesophageal cancer is an uncommon cause of death in patients with Barrett’s oesophagus.
GUT.
1996;
39
5-8
-
62
Sampliner R E.
Practice guidelines on the diagnosis, surveillance, and therapy of Barrett’s esophagus. The Practice Parameters Committee of the American College of Gastroenterology.
Am J Gastroenterol.
1998;
93 (7)
1028-1032
-
63
MacDonald C E, Wicks A C, Playford R J.
Final results from 10 year cohort of patients undergoing surveillance for Barrett’s oesophagus. Observational study.
Br Med J.
2000;
321
1252-1255
-
64
Sontag S J.
Preventing death of Barrett’s cancer: does frequent surveillance endoscopy do it?.
Am J Med.
2001;
3 (111 Suppl 8A)
137S-141
-
65
Corley D A, Levin T R, Habel L A. et al .
Surveillance and survival in Barrett’s adenocarcinoma; a population-based study.
Gastroenterology.
2002;
122
633-640
-
66
Parrilla P, de Martinez Haro LF, Ortiz A. et al .
Standard antireflux operations in patients who have Barrett’s esophagus. Current results.
Chest Surg Clin N Am.
2002;
12
113-126
-
67
Carlson M A, Frantzides C T.
Complications and results of primary minimally invasive antireflux procedures: a review of 10,735 reported cases.
J Am Coll Surg.
2001;
193 (4)
428-439
-
68
Schäfer H, Collet P, Wolfgarten E. et al .
Endoskopische Gastroplastik zur Behandlung der gastroösophagealen Refluxerkrankung - eine Pilotstudie.
Visceralchirurgie.
2001;
36
362-366
-
69
Devière J, Pastorelli A, Louis H. et al .
Endoscopic implantation of a biopolymer in the lower esophageal sphincter for gastroesophageal reflux: a pilot study.
Gastrointest Endosc.
2002;
55 (3)
335-341
-
70
Triadafilopoulos G, DiBaise J K, Nostrant T T. et al .
The Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the U.S. open label trial.
Gastrointest Endosc.
2002;
55 (2)
149-156
-
71
Wolfsen H C, Richards W O.
The Stretta procedure for the treatment of GERD: a registry of 558 patients.
J Laparoendosc Adv Surg Tech.
2002;
12
395-402
-
72
Mahmood Z, McMahon B P, Arfin Q. et al .
Endocinch therapy for gastro-oesophageal reflux disease: a one year prospective follow up.
Gut.
2003;
52 (1)
34-39
-
73
Peters J H, Silverman D E, Stein A.
Lower esophageal sphincter injection of a biocompatible polymer.
Surg Endosc.
2003;
17 (4)
547-550
-
74
Heudebert G R, Marks R, Wilcox M. et al .
Choice of long-term strategy for the management of patients with severe esophagitis: a cost-utility analysis.
Gastroenterology.
1997;
112
1078-1086
-
75
Myrvold H E, Lundell L, Miettinen P. et al and the Nordic GORD Study Group. .
The cost of long term therapy for gastro-oesophageal reflux disease: a randomised trial comparing omeprazole and open antireflux surgery.
Gut.
2001;
49 (4)
488-494
-
76
O’Connor J B, Provenzale D, Brazer S.
Economic considerations in the treatment of gastroesophageal reflux disease: a review.
Am J Gastroenterol.
2000;
95 (12)
3356-3364
-
77
Sonnenberg A.
Motion - laparoscopic Nissen fundoplication is more cost effective than oral PPI administration: arguments against the motion.
Can J Gastroenterol.
2002;
16
627-631
-
78
Swanström L L.
Motion - laparoscopic Nissen fundoplication is more cost effective than oral PPI administration: arguments for the motion.
Can J Gastroenterol.
2002;
16
621-623
-
79
Hadorn D C, Baker D.
Development of the AHCPR-sponsored heart failure guideline: methodologic and procedural issues.
Jt Comm J Qual Improv.
1994;
20
539-547
-
80 Bollschweiler E. Nationale und klinikinterne Leitlinien: Definition und Problemlage. Lauterbach KW, Schrappe M Gesundheitsökonomie, Qualitätsmanagement und Evidence-based Medicine Stuttgart; Schattauer-Verlag 2001: 457-462
Prof. Dr. A. H. Hölscher
Klinik und Poliklinik für Visceral- und Gefäßchirurgie der Universität zu Köln
Joseph-Stelzmann-Str. 9
50931 Köln
Email: Arnulf.Hoelscher@medizin.uni-koeln.de
